"use client";

export default function RetatrutideFattyLiverPage() {
  return (
    <>
      <head>
        <title>Retatrutide and Fatty Liver: 86% Liver Fat Reduction in Phase 2 Data | RevitalizeMe</title>
        <meta name="description" content="Retatrutide reduced liver fat by over 80% and resolved MASLD in 9 of 10 patients. Here&apos;s what the Phase 2 data means and how to find out if you&apos;re at risk." />
        <meta property="og:title" content="Retatrutide and Fatty Liver: 86% Liver Fat Reduction in Phase 2 Data" />
        <meta property="og:type" content="article" />
      </head>
      <div className="min-h-screen bg-white">
        <header className="border-b border-gray-200">
          <div className="max-w-3xl mx-auto px-4 py-4 flex items-center justify-between">
            <span className="font-display text-lg text-[#294547]">RevitalizeMe<sup className="text-xs">®</sup></span>
            <span className="text-xs tracking-widest uppercase text-[#5A6B6E]">Liver Health</span>
          </div>
        </header>
        <article className="max-w-[720px] mx-auto px-4 pt-10 sm:pt-14 pb-16">
          <h1 className="text-[26px] sm:text-[30px] font-bold text-[#1A1A2E] leading-snug mb-4">
            Retatrutide and Fatty Liver: Why Metabolic Doctors Are Watching the TRIUMPH Trials
          </h1>
          <p className="text-sm text-[#5A6B6E] mb-10">
            By Dr. Cyrus, MD &bull; February 2026 &bull; 9 min read
          </p>

          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>One in three adults has it. Most do not know.</p>
            <p>
              Metabolic dysfunction-associated steatotic liver disease &mdash; MASLD, formerly called NAFLD &mdash; has quietly become one of the most common chronic diseases in the world. Its prevalence has climbed from 25 percent of the global population in 2006 to 38 percent by 2019, driven almost entirely by rising rates of obesity and insulin resistance.
            </p>
            <p>
              Unlike most diseases at this scale, fatty liver has no obvious symptoms in its early stages. No pain. No fatigue. No warning signs. By the time symptoms appear, the disease has often progressed from simple fat accumulation to active inflammation (MASH, formerly NASH), fibrosis, and in the worst cases, cirrhosis or liver cancer.
            </p>
            <p>
              The first FDA-approved medication for MASH &mdash; resmetirom &mdash; arrived in March 2024. But a triple agonist called retatrutide is producing liver fat reduction data that has hepatologists paying close attention. Here is what the numbers show and why this matters even if you do not think of yourself as someone with liver disease.
            </p>
          </div>

          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            The Disease Nobody Sees
          </h2>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              Your liver is not just a filter. It is a metabolic factory &mdash; processing nutrients, regulating blood sugar, producing cholesterol, manufacturing proteins, and storing energy.
            </p>
            <p>
              Fatty liver disease begins when excess calories, insulin resistance, and dysregulated fat metabolism cause triglycerides to accumulate in liver cells. A healthy liver contains less than 5 percent fat by volume. At 10 percent or above, you meet diagnostic criteria for MASLD.
            </p>
            <p>
              At this stage, the damage is reversible. The liver is remarkably good at healing itself &mdash; if the underlying cause is addressed.
            </p>
            <p>
              But left unchecked, fat accumulation triggers an inflammatory response. This is MASH &mdash; the inflamed, progressive form. MASH can progress to fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. It is now one of the fastest-growing indications for liver transplantation in the United States.
            </p>
          </div>

          <div className="bg-gray-50 border border-gray-200 rounded-xl p-6 sm:p-8 mb-10">
            <p className="text-xs uppercase tracking-widest text-[#5A6B6E] font-semibold mb-4">The Progression</p>
            <div className="flex flex-col sm:flex-row items-center justify-between gap-3 text-center">
              <div className="flex-1 px-2">
                <p className="text-[13px] sm:text-sm font-semibold text-[#1A1A2E]">Healthy Liver</p>
              </div>
              <span className="text-[#81D9DE] text-lg sm:text-xl">→</span>
              <div className="flex-1 px-2">
                <p className="text-[13px] sm:text-sm font-semibold text-[#1A1A2E]">Fatty Liver (MASLD)</p>
              </div>
              <span className="text-[#81D9DE] text-lg sm:text-xl">→</span>
              <div className="flex-1 px-2">
                <p className="text-[13px] sm:text-sm font-semibold text-[#1A1A2E]">Inflammation (MASH)</p>
              </div>
              <span className="text-[#81D9DE] text-lg sm:text-xl">→</span>
              <div className="flex-1 px-2">
                <p className="text-[13px] sm:text-sm font-semibold text-[#1A1A2E]">Fibrosis</p>
              </div>
              <span className="text-[#81D9DE] text-lg sm:text-xl">→</span>
              <div className="flex-1 px-2">
                <p className="text-[13px] sm:text-sm font-semibold text-[#1A1A2E]">Cirrhosis</p>
              </div>
            </div>
          </div>

          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              Every arrow represents a window of opportunity. The earlier you intervene, the more reversible the damage is.
            </p>
          </div>

          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            Why Current GLP-1 Medications Help &mdash; But Have Limits
          </h2>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              Semaglutide and tirzepatide both reduce liver fat. Weight loss alone drives significant improvement, and the insulin-sensitizing effects of GLP-1 medications provide additional benefit.
            </p>
            <p>
              But these medications work primarily through appetite suppression and insulin signaling. They reduce the caloric surplus that drives fat into the liver, and they improve the metabolic environment that keeps it there. What they do not do &mdash; at least not robustly &mdash; is directly increase the rate at which the liver burns its existing fat stores.
            </p>
            <p>
              This is where the glucagon receptor changes the equation.
            </p>
          </div>

          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            The Glucagon Advantage: Targeting the Liver Directly
          </h2>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              Glucagon has long been understood as insulin&apos;s counterpart. But its metabolic effects extend far beyond glucose. Glucagon receptor activation in the liver promotes fat oxidation (burning stored fat for energy), decreases lipogenesis (the creation of new fat), improves glycogen mobilization, and reduces hepatic inflammation.
            </p>
            <p>
              In practical terms, the glucagon receptor tells the liver: stop storing fat and start burning it.
            </p>
            <p>
              This is the mechanism that makes retatrutide fundamentally different from semaglutide or tirzepatide for liver disease.
            </p>
          </div>

          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            What the Data Shows
          </h2>

          <div className="bg-[#294547] rounded-xl p-6 text-center mb-8">
            <span className="font-display text-4xl sm:text-5xl text-[#81D9DE] block mb-2">86%</span>
            <p className="text-white/90 text-sm sm:text-base max-w-md mx-auto">
              liver fat reduction at 48 weeks on retatrutide 12 mg. Nine out of ten patients no longer met diagnostic criteria for fatty liver disease.
            </p>
          </div>

          <div className="bg-gray-50 border border-gray-200 rounded-xl p-6 sm:p-8 mb-10">
            <div className="space-y-6">
              <div>
                <p className="text-xs uppercase tracking-widest text-[#5A6B6E] font-semibold mb-4">At 48 Weeks</p>
                <div className="space-y-3">
                  <div className="flex justify-between items-center pb-2 border-b border-gray-300">
                    <span className="text-sm text-[#1A1A2E]">8 mg dose</span>
                    <span className="font-semibold text-[#294547]">81.7% liver fat reduction</span>
                  </div>
                  <div className="flex justify-between items-center pb-2 border-b border-gray-300">
                    <span className="text-sm text-[#1A1A2E]">12 mg dose</span>
                    <span className="font-semibold text-[#294547]">86.0% liver fat reduction</span>
                  </div>
                  <div className="flex justify-between items-center">
                    <span className="text-sm text-[#1A1A2E]">Placebo</span>
                    <span className="font-semibold text-[#294547]">increased 4.6%</span>
                  </div>
                </div>
              </div>
              <div className="border-t border-gray-300 pt-6">
                <p className="text-xs uppercase tracking-widest text-[#5A6B6E] font-semibold mb-4">Steatosis Resolution (Liver Fat Below 5%)</p>
                <div className="space-y-3">
                  <div className="flex justify-between items-center pb-2 border-b border-gray-300">
                    <span className="text-sm text-[#1A1A2E]">8 mg dose</span>
                    <span className="font-semibold text-[#294547]">89%</span>
                  </div>
                  <div className="flex justify-between items-center pb-2 border-b border-gray-300">
                    <span className="text-sm text-[#1A1A2E]">12 mg dose</span>
                    <span className="font-semibold text-[#294547]">93%</span>
                  </div>
                  <div className="flex justify-between items-center">
                    <span className="text-sm text-[#1A1A2E]">Placebo</span>
                    <span className="font-semibold text-[#294547]">0%</span>
                  </div>
                </div>
              </div>
            </div>
          </div>

          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            The Metabolic Cascade
          </h2>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              In patients taking retatrutide at doses of 4 mg and above: fasting insulin dropped by 37 to 71 percent. HOMA-IR decreased by 36 to 69 percent. Adiponectin increased by 30 to 99 percent. Triglycerides fell by 35 to 40 percent. Leptin decreased by 30 to 56 percent.
            </p>
            <p>
              The investigators also found a nonlinear relationship: near-maximal liver fat reduction was achieved at approximately 20 percent body weight loss. This suggests that the liver responds early and dramatically to treatment.
            </p>
          </div>

          <div className="bg-[#F0F9FA] border border-[#81D9DE]/20 rounded-xl p-6 sm:p-8 -mx-2 sm:-mx-4 mb-12">
            <h2 className="font-display text-xl sm:text-2xl text-[#294547] text-center mb-3">
              Want to Learn How Triple Agonism Works?
            </h2>
            <p className="text-center text-[#5A6B6E] text-sm sm:text-base mb-6 max-w-lg mx-auto">
              Download our free Triple G Explained guide &mdash; how retatrutide targets three hormone receptors including the glucagon pathway that drives liver fat reduction. 9 pages, evidence-based, no upsell.
            </p>
            <form action="https://api.web3forms.com/submit" method="POST" className="max-w-md mx-auto flex flex-col gap-3">
              <input type="hidden" name="access_key" value="2e69ed75-e2a2-4eed-97c6-b1ace9d49897" />
              <input type="hidden" name="redirect" value="https://landing-page-generator-gamma.vercel.app/triple-g-explained/thank-you" />
              <input type="hidden" name="subject" value="New Lead: Retatrutide Fatty Liver Article" />
              <input type="hidden" name="from_name" value="RevitalizeMe Lead Magnet" />
              <input type="checkbox" name="botcheck" className="hidden" />
              <input type="text" name="name" required placeholder="First name" className="w-full px-4 py-3.5 rounded-lg border border-gray-300 bg-white text-base text-[#1A1A2E] placeholder:text-gray-400 outline-none transition-colors focus:border-[#81D9DE] focus:ring-2 focus:ring-[#81D9DE]/30" />
              <input type="email" name="email" required placeholder="Enter your email" className="w-full px-4 py-3.5 rounded-lg border border-gray-300 bg-white text-base text-[#1A1A2E] placeholder:text-gray-400 outline-none transition-colors focus:border-[#81D9DE] focus:ring-2 focus:ring-[#81D9DE]/30" />
              <button type="submit" className="w-full bg-[#294547] text-white font-semibold text-base py-3.5 rounded-lg hover:bg-[#3A5F62] transition-all cursor-pointer">
                Send Me the Free Guide
              </button>
            </form>
            <p className="text-center text-xs text-[#5A6B6E] mt-3">
              Free &bull; No spam &bull; Unsubscribe anytime
            </p>
          </div>

          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            Who Should Be Thinking About This
          </h2>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              You may be at risk if you have: a body mass index above 30, a waist circumference above 40 inches (men) or 35 inches (women), type 2 diabetes or prediabetes, insulin resistance, elevated triglycerides, or a family history of liver disease.
            </p>
            <p>
              <strong>Tests worth discussing with your provider:</strong>
            </p>
            <ul className="list-disc pl-6 space-y-2">
              <li>ALT and AST &mdash; liver enzymes</li>
              <li>FIB-4 score &mdash; estimates liver fibrosis likelihood</li>
              <li>FibroScan (transient elastography) &mdash; measures liver stiffness</li>
              <li>MRI-PDFF &mdash; most accurate liver fat measurement</li>
            </ul>
            <p>
              You do not need all of these. Starting with a FIB-4 calculation and a FibroScan if indicated gives you a reliable picture.
            </p>
          </div>

          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            The Bigger Picture
          </h2>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              Fatty liver disease is not a standalone condition. It is a manifestation of the same metabolic dysfunction that drives obesity, type 2 diabetes, cardiovascular disease, and metabolic syndrome.
            </p>
            <p>
              Current weight loss medications do this to varying degrees. Retatrutide, with its triple mechanism, has the potential to do it more comprehensively.
            </p>
            <p>
              But you do not have to wait for retatrutide. Semaglutide and tirzepatide both reduce liver fat meaningfully. Weight loss of any kind improves hepatic steatosis. A Mediterranean-style dietary pattern has shown consistent benefits for MASLD.
            </p>
            <p>
              The window for intervention is wide, but it is not infinite. Fatty liver that is diagnosed and addressed early is highly reversible. Fatty liver that progresses to fibrosis and cirrhosis is not. The best time to find out where you stand is before symptoms force the question.
            </p>
          </div>

          <div className="bg-[#294547] rounded-xl p-6 sm:p-8 text-center mb-12">
            <h2 className="font-display text-xl sm:text-2xl text-white mb-3">
              Ready to Take the First Step?
            </h2>
            <p className="text-[#81D9DE] text-sm sm:text-base leading-relaxed mb-6 max-w-lg mx-auto">
              Talk to a licensed provider about your metabolic health &mdash; including liver fat, insulin resistance, and whether weight loss treatment may help.
            </p>
            <a href="https://revitalizeme.com" className="inline-block bg-[#81D9DE] text-white font-semibold text-sm sm:text-base py-3 px-8 rounded-lg hover:brightness-90 transition-all mb-3">
              Start Your Free Consultation
            </a>
            <p className="text-white/70 text-xs mt-2">
              No commitment. No pressure. Just answers.
            </p>
          </div>
        </article>
        <footer className="border-t border-gray-200 py-6">
          <div className="max-w-[720px] mx-auto px-4 text-center">
            <p className="text-xs text-[#5A6B6E]/80 leading-relaxed max-w-xl mx-auto">
              This content is for educational purposes only and is not intended as medical advice. Retatrutide is an investigational medication not yet approved by the FDA. Always consult with a qualified healthcare provider before starting any treatment. Individual results may vary.
            </p>
            <p className="text-xs text-[#5A6B6E]/60 mt-3">
              &copy; 2026 RevitalizeMe
            </p>
          </div>
        </footer>
      </div>
    </>
  );
}